Fosciclopirox (Ciclopirox Prodrug)
Cisplatin-ineligible Muscle-Invasive Bladder Cancer (MIBC)
Key Facts
About CicloMed
CicloMed LLC is a private, developmental-stage oncology company headquartered in Kansas City, USA, founded in 2006. Its core asset is Fosciclopirox, a prodrug of the antifungal agent ciclopirox, which is being repurposed as an intravesical and systemic therapy for bladder cancer, with ongoing Phase I clinical studies. The company emerged from a public-private partnership with The University of Kansas Cancer Center and is a portfolio company of BioNovus Innovations LLC, leveraging a team with deep expertise in drug development and oncology to address a significant unmet medical need.
View full company profileAbout CicloMed
CicloMed LLC is a private, developmental-stage oncology company headquartered in Kansas City, USA, founded in 2006. Its core asset is Fosciclopirox, a prodrug of the antifungal agent ciclopirox, which is being repurposed as an intravesical and systemic therapy for bladder cancer, with ongoing Phase I clinical studies. The company emerged from a public-private partnership with The University of Kansas Cancer Center and is a portfolio company of BioNovus Innovations LLC, leveraging a team with deep expertise in drug development and oncology to address a significant unmet medical need.
View full company profileAbout CicloMed
CicloMed LLC is a private, developmental-stage oncology company headquartered in Kansas City, USA, founded in 2006. Its core asset is Fosciclopirox, a prodrug of the antifungal agent ciclopirox, which is being repurposed as an intravesical and systemic therapy for bladder cancer, with ongoing Phase I clinical studies. The company emerged from a public-private partnership with The University of Kansas Cancer Center and is a portfolio company of BioNovus Innovations LLC, leveraging a team with deep expertise in drug development and oncology to address a significant unmet medical need.
View full company profile